FGFR4

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
PDT, Research, Conference, Interest, ATS, Biologics license application, Patient, SAN, Howard University, Knowledge, EAP, ATyr Pharma, EDT, NRP2, American Thoracic Society, Downstream, Investment, Clinical trial, Small RNA, Neuropilin, Myelocyte, Safety, Sarcoidosis, Immune system, FGF2, FGFR4, BLA, Pharmaceutical industry

SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
  • Interested parties may access the call by registering here in order to obtain a dial in, personalized passcode and webcast information.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
SAN, ILD, GLOBE, Review, Private Securities Litigation Reform Act, Forward-looking statement, IND, Intellectual property, Investment, ATyr Pharma, Patent, NRP2, FDA, FC, Food, Inflammation, EST, Research, Biology, Risk, Proteomics, Drug discovery, Interstitial lung disease, Interest, Sarcoidosis, SEC, Goal, AARS, Safety, PST, FGFR4, Neuropilin, Food and Drug Administration, Biomarker, Cancer, D, Degenerative disease, Patient, RNA transfection, Therapy, Systemic scleroderma, COVID-19, Pharmaceutical industry, Fine chemical

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.

Key Points: 
  • Ended the third quarter 2022 with $79.6 million in cash, restricted cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2022 results and provided a corporate update.
  • Announced the publication of results of the Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis in the peer-reviewed medical journal CHEST.
  • G&A Expenses: General and administrative expenses were $3.6 million for the third quarter of 2022.

Tyra Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Investor, Fibroblast growth factor receptor 1, Nasdaq, Cancer, SNP, Webcast, Fibroblast growth factor receptor, Chromosomal rearrangement, CA, FGFR4, Transfection, Company, Science, Conference, FGFR, Patient, CEO, FGFR3, Achondroplasia, FGFR2, RET, Pharmaceutical industry, Security (finance), Cholangiocarcinoma

Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.

Key Points: 
  • Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
  • Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers.

Tyra Biosciences Announces Planned Chief Financial Officer Transition

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Agricultural economics, Growth, Montana State University, FGFR3, Risk, CEO, Vinylcyclopropane rearrangement, Fibroblast growth factor receptor, MicroRNA, Acquisition, U.S. Securities and Exchange Commission, Annual report, Daiichi Sankyo, FGFR, SEC, Cancer, Esperies, Research, AbbVie, FGFR4, Regeneron Pharmaceuticals, Business administration, Esperion Therapeutics, IND, Nasdaq, COVID-19, FGFR2, Agriculture, Fibroblast growth factor receptor 1, Eli Lilly, SNP, CFO, Form 10-K, RET, Sale, PricewaterhouseCoopers, Private Securities Litigation Reform Act, Achondroplasia, Transfection, Therapy, FDA, Patient, Audit committee, Cooper, Science, CA, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022. TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition. 

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
  • TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition.
  • Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
  • "It has been my privilege to serve as Chief Financial Officer of TYRA since shortly after the company's inception," said Ms. van den Boom.

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

Retrieved on: 
Tuesday, October 11, 2022
SAN, Proteomics, Therapy, SEC, Risk, Biotechnology, Biology, Research, RNA transfection, Private Securities Litigation Reform Act, Drug discovery, IP, FGFR4, AARS, ATyr Pharma, GLOBE, Intellectual property, Forward-looking statement, COVID-19, LIFE, Fine chemical, Pharmaceutical industry

We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.

Key Points: 
  • We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.
  • aTyr intends to interrogate the interaction between this fragment of AARS and FGFR4 to determine potential therapeutic indications.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • Dualsystems Biotech is a privately held biotechnology company established in 2006 as a spin-off from the University Zurich, Switzerland.

Tyra Biosciences to Participate at September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022
CA, Achondroplasia, Cancer, Fibroblast growth factor receptor 1, SNP, FGFR, Fibroblast growth factor receptor, RET, LinkedIn, Science, FGFR4, Chromosomal rearrangement, Nasdaq, Transfection, FGFR2, FGFR3, Patient, Medical imaging, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:
    Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • Leveraging SNP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.
  • TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers.

aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Monday, August 15, 2022
FDA, FC, LIFE, FGFR4, ATS, Biomarker, Risk, ATyr Pharma, Inflammation, Forward-looking statement, GLOBE, AARS, Private Securities Litigation Reform Act, SEC, Investment, Clinical trial, Research, Ethics, Cancer, Neuropilin, American Thoracic Society, Fibrosis, Patient, Review, Therapy, COVID-19, SAN, D, NRP2, International Conference on Emerging Infectious Diseases, Safety, PDT, Sarcoidosis, Biology, Food and Drug Administration, Goal, Degenerative disease, EDT, Fast Track, Interest, Conference, Food, Disease, RNA transfection, Pharmaceutical industry

SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update.

Key Points: 
  • Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments.
  • SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update.
  • The company is on track to enroll the first patient in the study in the third quarter of 2022.
  • G&A Expenses: General and administrative expenses were $3.4 million for the second quarter of 2022.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Market Insights 2022: Coverage of 15 Companies and Respective Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, Health, Clinical Trials, Antagonist, Patient, Fibroblast growth factor receptor 4, HCC, Pemigatinib, II, FGFR4, Receptor tyrosine kinase, Therapy, FGFR2, Clinical trial, Discovery, Hepatocellular carcinoma, BTC, FGFR, News, Fine chemical, Pharmaceutical industry

This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.

Key Points: 
  • This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment
    This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

Retrieved on: 
Tuesday, June 14, 2022
DARS, Fibrosis, Goal, Biology, Research, ATyr Pharma, LIFE, Forward-looking statement, Cell proliferation, CEO, RNA transfection, Cancer, Disease, Inflammation, Therapy, Method, GLOBE, FGFR4, Private Securities Litigation Reform Act, Risk, COVID-19, AARS, Poster, SAN, SEC, Drug discovery, CO, Pharmaceutical industry

SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that new findings from its platform will be presented in a poster today at the Keystone Symposia Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapeutics in Keystone, CO.

Key Points: 
  • The poster presents findings from aTyrs innovative tRNA synthetase platform, whereby selected fragments of Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) were found to bind to the surface of specific human cell types via novel binding partners.
  • Additionally, the target receptor of the fragment AARS-1 was identified as fibroblast growth factor receptor 4 (FGFR4), indicating that AARS-1 may have therapeutic potential in fibrosis, inflammation and cancer.
  • The target receptor identified for the fragment AARS-1, FGFR4, is involved in many cellular processes including cell proliferation, differentiation and tissue repair.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform.

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Wednesday, January 19, 2022
IC50, Patient, KNTE, MBBS, Gastrointestinal cancer, SAN, FGFR, Clinical trial, Cholangiocarcinoma, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, FGFR2, Growth, EC50, HIV disease progression rates, Poster, GLOBE, Â, Cancer, FGFR1, Translational medicine, U.S. Securities and Exchange Commission, Nasdaq, Industry, Program, FGFR3, Therapy, Food, Immortalised cell line, ASCO, Investigational New Drug, FGFR4, Security (finance), Fibroblast growth factor receptor, Risk, ICC, Pharmaceutical industry

These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.

Key Points: 
  • These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.
  • Oncogenic FGFR (FGFR1, FGFR2, FGFR3, and FGFR4) gene alterations are observed in approximately 7% of all human cancers.
  • KIN-3248 has been evaluated across wild-type FGFR family members and clinically relevant fusions and kinase domain resistance mutations in vitro.
  • Additional information on the ASCO GI Cancers Symposium is available through the conference website at: https://conferences.asco.org/gi .